Evidence map›Paper›PMID 29618558›Full record

ArticleStroke2018

Unmet Needs and Challenges in Clinical Research of Intracerebral Hemorrhage.

Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants

Abstract read
In one paragraph

Article in Stroke, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Optimized lactoferrin as a highly promising treatment for intracerebral hemorrhage: Pre-clinical experience.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants

Funding

NSTN National Clinical Coordinating CenterU01NS086872 · NINDS · UNIVERSITY OF CINCINNATI · PI Joseph Paul Broderick, Pooja Khatri · 2013 to 2026
$32.3M
Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (i-DEF)U01NS074425 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SELIM, MAGDY H · 2012 to 2016
$8.7M
Safety and Tolerability of Deferoxamine in Acute Cerebral HemorrhageR01NS057127 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SELIM, MAGDY H · 2008 to 2010
$1.0M
NINDS NIH HHS R01 NS057127NINDS NIH HHS U01 NS074425NINDS NIH HHS U01 NS086872
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomedical ResearchCerebral HemorrhageClinical Trials as TopicHumansOutcome Assessment, Health CarePatient SelectionReference StandardsResearchResearch DesignSeverity of Illness IndexTime Factorscerebral hemorrhageclinical researchHEADSrecommendations

Identifiers

PMID29618558
PMCPMC5916316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.